Clinical interest in Lp(a) has grown exponentially in recent times, as an assortment of epidemiological studies has pinpointed the link between plasma Lp(a) concentrations (reported as ≥300 mg/L or ≥30 mg/dL) and the risk of suffering coronary events, peripheral artery disease, cerebrovascular disease, and the early development of atherosclerosis in children and adolescents [13, 14]. This evidence concerns the gene LPA and peripheral arterial disease.